计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
T412004-1mg |
1mg |
期货 ![]() |
| |
T412004-5mg |
5mg |
期货 ![]() |
| |
T412004-10mg |
10mg |
期货 ![]() |
|
产品名称 | Tocilizumab (anti-IL-6R) |
---|---|
别名 | 托珠单抗; Tocilizumab (anti-IL-6R); Recombinant Tocilizumab Antibody; Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab); MRA; Anti-Human IL6R; Humanized Antibody; Tocilizumab; CD 126 antibody; CD126 antibody; CD126 antigen antibody; Gp80 antibody; IL 6R 1 |
英文别名 | Tocilizumab (anti-IL-6R); Recombinant Tocilizumab Antibody; Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab); MRA; Anti-Human IL6R; Humanized Antibody; Tocilizumab; CD 126 antibody; CD126 antibody; CD126 antigen antibody; Gp80 antibody; IL 6R 1 antibo |
规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
特异性 | IL-6Ra/CD126 |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
反应种属 | Cynomolgus,Human |
抗体类型 | Primary antibody |
---|---|
Format | Whole IgG |
亚型 | Human IgG1 |
轻链亚型 | Kappa |
SDS-PAGE | 26.6 kDa (Light Chain) & 51.4 kDa (Heavy Chain), under reducing conditions; 174.3 kDa, under non-reducing conditions. |
纯化方法 | Protein A purified |
来源 | CHO supernatant |
物理外观 | Liquid |
储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
防腐剂 | No |
浓度 | Lot by Lot |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS编号和信息 | 375823-41-9 |
IMGT/mAb-DB | 96 |
---|---|
PubChem SID | 178103463 |
Wikipedia | Tocilizumab |
PEP | tocilizumab |
Immunopaedia Search | tocilizumab |
Reactome Reaction | R-HSA-9681294 |
Reactome Drug | R-ALL-9681301 |
输入批号以搜索COA:
1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al.. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.. Arthritis Rheum, 54 (9): (2817-29). [PMID:16947782] |
2. Paul-Pletzer K. (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.. Drugs Today, 42 (9): (559-76). [PMID:17028666] |
3. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. (2007) Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.. Intern Med, 46 (11): (771-4). [PMID:17541233] |
4. Nishimoto N, Kishimoto T. (2008) Humanized antihuman IL-6 receptor antibody, tocilizumab.. Handb Exp Pharmacol, 71 (181): (151-60). [PMID:18071945] |
5. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.. Int Immunopharmacol, 5 (12): (1731-40). [PMID:16102523] |
6. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. (2005) Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.. Clin Rev Allergy Immunol, 28 (3): (231-8). [PMID:16129907] |
7. Ohsugi Y, Kishimoto T. (2008) The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.. Expert Opin Biol Ther, 8 (5): (669-81). [PMID:18407769] |
8. Unizony S, Kermani TA. (2018) IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis.. J Neuroophthalmol, 38 (4): (551-558). [PMID:30199509] |
9. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J et al.. (2021) Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.. JAMA Intern Med, 181 (1): (41-51). [PMID:33080002] |
10. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C et al.. (2021) Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (24-31). [PMID:33080005] |
11. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, CORIMUNO-19 Collaborative Group. (2021) Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.. JAMA Intern Med, 181 (1): (32-40). [PMID:33080017] |
12. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM et al.. (2020) Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.. N Engl J Med, 383 (24): (2333-2344). [PMID:33085857] |
13. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B et al.. (2020) Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.. Clin Infect Dis, 71 (8): (1937-1942). [PMID:32301997] |
14. Wang W, Liu X, Wu S, Chen S, Li Y, Nong L, Lie P, Huang L, Cheng L, Lin Y et al.. (2020) Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.. J Infect Dis, 222 (9): (1444-1451). [PMID:32601708] |